Protective Provisions in Pre-IPO Financing: A Checklist of Investor Veto Rights Over Key Matters

The decision by the Hong Kong Stock Exchange (HKEX) to reject the listing application of a mainland Chinese biotech firm in Q1 2025, citing a shareholder veto right that effectively gave a single Pre-IPO investor control over the company’s core asset disposal, has sent a clear signal to the market. The HKEX Listing Division, in its decision letter, noted that the protective provision in question — a supermajority requirement for any sale of intellectual property — constituted a “disproportionate control mechanism” inconsistent with the principle of equitable treatment of shareholders under Listing Rule 2.03(3). This single ruling has reshaped the negotiation dynamics for every Pre-IPO financing round structured in Hong Kong or involving a Hong Kong-listed vehicle. For CFOs and their legal advisors, the era of drafting a standard “negative consent” list of investor veto rights without a forensic review of each clause’s potential impact on listing suitability is over. The following checklist provides a structured framework for evaluating which protective provisions are market-standard and which create a material risk of HKEX rejection.

The Core Tension: Investor Protection vs. Listing Rule Compliance

The fundamental conflict in Pre-IPO financing lies between the investor’s desire for veto rights over fundamental corporate actions and the HKEX’s requirement that a listed company be managed by its board of directors in the interests of all shareholders. The HKEX’s Guidance Letter HKEX-GL86-16, updated in 2024, explicitly states that any shareholder agreement that restricts the board’s discretion on matters of “strategic importance” may be scrutinised for compliance with the Listing Rules. The practical consequence is that a veto right that is acceptable in a Cayman Islands or BVI private company may become a disqualifying factor in a Hong Kong Main Board listing application.

The “Disproportionate Control” Trap

The HKEX’s focus is on whether a protective provision creates a situation where a minority shareholder can block a decision that the board, acting in the best interests of the company, believes is necessary. The biotech case from Q1 2025 illustrates this precisely: the investor held a 12% stake but had a veto over any disposal of IP assets valued above HKD 50 million. The HKEX determined that this gave the investor effective control over the company’s core business strategy, violating the principle that all shareholders in a listed company should be treated equally. Any Pre-IPO term sheet must therefore be stress-tested against this standard: does the veto right allow a minority holder to block a transaction that a majority of disinterested shareholders would approve?

The Sponsor’s Due Diligence Mandate

Under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (SFC Code), specifically paragraph 17.6, a sponsor is required to identify any “material restrictions” on a listing applicant’s business. The sponsor’s due diligence report must now explicitly address any shareholder veto rights. The HKEX’s practice, as evidenced in recent listing decisions, is to require a full copy of the shareholders’ agreement and any side letters. A failure to disclose a veto right that is later discovered by the HKEX can lead to a rejection or, post-listing, a referral to the SFC’s enforcement division. The sponsor’s legal team will typically demand that any veto rights be limited to a “reserved matters” list that is customary for a Hong Kong-listed company.

The Veto Rights Checklist: What Is Market Standard

The following checklist categorises protective provisions into three tiers: those that are generally acceptable, those that require careful structuring, and those that are almost certain to trigger HKEX scrutiny. This classification is based on analysis of prospectuses filed with the HKEX between 2022 and 2025, as well as the HKEX’s published listing decisions.

Tier 1: Generally Acceptable Veto Rights

These rights are considered standard in Pre-IPO financings and are unlikely to cause issues, provided they are not structured to give a single investor a blocking stake on matters that are core to the company’s strategy. The HKEX’s position is that these rights are protective of minority interests, not controlling.

• Changes to the constitutional documents: A veto over amendments to the memorandum and articles of association is standard. This protects the investor’s fundamental contractual rights.
• Changes to share capital: A veto over the creation of a new class of shares or an increase in authorised share capital is typical. This prevents dilution without the investor’s consent.
• Voluntary winding up or liquidation: A veto over a voluntary winding-up resolution is standard. This ensures the investor can block a decision to dissolve the company without their agreement.
• Related party transactions above de minimis thresholds: A veto over transactions with the founder or other controlling shareholders that exceed a fixed percentage of net assets (e.g., 1% to 3%) is standard. This aligns with the Listing Rules’ requirements for connected transactions under Chapter 14A.
• Appointment of auditors: A veto over the appointment or removal of the company’s auditors is standard. This protects the integrity of financial reporting.

Tier 2: Structurally Sensitive Veto Rights

These rights are common but require careful calibration of thresholds, scope, and duration. The HKEX will examine whether the veto right effectively gives the investor control over the company’s business strategy.

• Approval of the annual business plan and budget: This is a contentious area. A veto over the annual budget can be interpreted as giving the investor control over the company’s operational direction. The market standard is to allow the investor to comment on the budget but not to veto it. If a veto is granted, it must be limited to a specific category of expenditure (e.g., capital expenditure above a certain amount) and should sunset upon listing.
• Appointment and removal of directors: A veto over the appointment of a specific class of director (e.g., a non-executive director nominated by the investor) is standard. However, a veto over the removal of the CEO or CFO is problematic. The HKEX expects the board to have the power to remove senior management. The compromise is a requirement for a “cause” standard for removal, coupled with a right for the investor to appoint a replacement.
• Entry into material contracts: A veto over contracts above a specific value is common. The risk arises when the threshold is set too low, effectively giving the investor a veto over all significant commercial decisions. The threshold should be set as a percentage of the company’s market capitalisation or net assets at the Pre-IPO valuation, and the scope should be limited to contracts outside the ordinary course of business.
• Acquisitions and disposals: A veto over acquisitions or disposals of assets above a certain value is standard. The threshold should be calibrated to the company’s size. A veto over the sale of the company’s core business or all or substantially all of its assets is generally acceptable, as this is a fundamental change. A veto over the sale of a minor subsidiary is not.

Tier 3: High-Risk Veto Rights

These provisions are almost certain to be flagged by the HKEX and may lead to a rejection or a requirement for their removal prior to listing. The burden of proof is on the applicant to demonstrate that the provision does not constitute disproportionate control.

• Veto over the listing itself: Any provision that requires the investor’s consent for the company to proceed with an IPO is a direct violation of the principle that the board and shareholders should decide on a listing. This is an absolute disqualifier.
• Veto over the appointment of the sponsor or legal counsel: This gives the investor control over the listing process itself. The HKEX will view this as an unacceptable restriction on the company’s ability to comply with its listing obligations.
• Veto over the company’s dividend policy: A veto over the declaration or amount of dividends gives the investor control over the company’s capital allocation policy. This is not acceptable. The investor’s protection should come from a right to a pro-rata dividend, not a veto over its declaration.
• Veto over the issuance of new securities (broadly defined): While a veto over the issuance of shares that would dilute the investor’s stake below a certain threshold is standard, a blanket veto over any issuance of new securities is not. This restricts the company’s ability to raise capital.
• Veto over changes to the company’s business scope: A veto over a change in the company’s line of business is generally acceptable if it is a fundamental change. A veto over the company entering a new market or launching a new product line is not. This is a direct restriction on the board’s management discretion.

Structural Solutions: The Sunset Clause and the “Springing” Right

The most effective method to manage the tension between investor protection and listing suitability is the use of a sunset clause. This provision automatically terminates the investor’s veto rights upon the occurrence of a specific event, typically the filing of the listing application (A1 submission) or the completion of the IPO. The HKEX has indicated in its Guidance Letter GL86-16 that a sunset clause is a strong factor in favour of finding a provision acceptable.

The “Springing” Veto Right

A more sophisticated structure is the “springing” veto right, which only becomes operative upon the occurrence of a specified event, such as a material breach of the investment agreement by the founder or a failure to meet a specific performance milestone. This structure avoids the HKEX’s concern about a permanent restriction on the board’s discretion. The investor retains a powerful remedy without creating a permanent governance conflict. This structure is increasingly common in Pre-IPO rounds where the investor is taking a significant minority stake (e.g., 15% to 30%) but does not want to be seen as a controlling shareholder.

The “Disinterested Shareholder” Approval Mechanism

Another solution is to require that any veto right be exercised only if the matter is not approved by a majority of the disinterested shareholders. This effectively converts the investor’s veto into a right to require a shareholder vote, which is consistent with the Listing Rules’ approach to connected transactions. This mechanism is particularly useful for veto rights over related party transactions and material contracts, as it aligns the investor’s protection with the regulatory framework that will apply post-listing.

The Post-Listing Transition: From Veto to Standard Governance

The negotiation of Pre-IPO protective provisions must also consider the transition to a listed company governance structure. The investor’s veto rights will not survive the IPO unless they are expressly incorporated into the company’s articles of association, which is highly unusual for a Hong Kong Main Board listing. The standard practice is for the investors’ rights to be governed by a shareholders’ agreement that terminates upon listing.

The Investor’s Post-Listing Toolkit

The investor’s protection post-listing will be derived from the Listing Rules themselves, not from a private contract. The key protections include:

• Connected transaction rules (Chapter 14A): Any transaction between the company and a controlling shareholder (including a Pre-IPO investor who becomes a substantial shareholder) requires disclosure and, in some cases, independent shareholder approval.
• Major transaction rules (Chapter 14): Any acquisition or disposal that exceeds certain thresholds requires shareholder approval, with the controlling shareholder abstaining from voting.
• Notifiable transaction rules (Chapter 14): Any transaction above a certain size must be announced.
• Right to requisition an extraordinary general meeting (EGM): A shareholder holding 5% or more of the voting shares can requisition an EGM under the Companies Ordinance (Cap. 622).
• Right to appoint a director: If the investor holds more than 10% of the voting shares, they can propose a director for election at a general meeting.

The “Locked-Box” vs. “Completion Accounts” Debate

The protective provisions around financial reporting are also critical. The choice between a locked-box mechanism (where the price is fixed and the investor bears the risk of profit leakage) and a completion accounts mechanism (where the price is adjusted based on a post-closing balance sheet) has direct implications for the veto rights over the company’s financial operations. A locked-box structure typically requires a stronger set of covenants against profit leakage, which can be enforced through a veto over certain distributions or transactions. A completion accounts structure places more emphasis on the audit process and the investor’s right to review the completion accounts. The HKEX’s preference, as stated in its Listing Decisions, is for a clear and auditable mechanism that does not give the investor a veto over the company’s day-to-day financial management.

Actionable Takeaways

1. Sunset every veto right. Every protective provision granted to a Pre-IPO investor must contain a clear sunset clause that terminates the right upon the filing of the listing application (A1 submission) or, at the latest, upon the commencement of trading.
2. Stress-test veto thresholds. Any veto right over a transaction should be calibrated as a percentage of the company’s market capitalisation at the Pre-IPO valuation, not a fixed HKD amount, to avoid the risk of the threshold becoming too low as the company grows.
3. Avoid any veto over the listing process itself. A provision requiring the investor’s consent for the appointment of the sponsor, legal counsel, or for the filing of the listing application is a disqualifying factor under HKEX Listing Rules.
4. Use the “disinterested shareholder” mechanism. For veto rights over related party transactions and material contracts, structure the right as a requirement for approval by a majority of disinterested shareholders, aligning with Chapter 14A of the Listing Rules.
5. Document the rationale. The sponsor’s due diligence report should include a clear memorandum explaining why each veto right is necessary for investor protection and why it does not constitute disproportionate control, citing the relevant HKEX Guidance Letters and Listing Decisions.